Highest-materiality recent filing
Arcus Q1 net loss $128M, cash $876M; discontinues Phase 3 STAR-121 in NSCLC
Net loss $128M for Q1 2026 vs $112M Q1 2025; revenue $17M down from $28M.
Arcus discontinues Phase 3 STAR-121 NSCLC trial; Gilead lets option rights lapse
STAR-121 evaluating domvanalimab + zimberelimab + chemo vs pembro + chemo in 1L metastatic NSCLC stopped by IDMC for futility.
Arcus Biosciences reports Q4 net loss $106M; casdatifan shows 45% cORR in late-line kidney cancer
Q4 2025 net loss $106M vs $94M YoY; revenue $33M; cash, equivalents & marketable securities $1.0B.
Arcus Biosciences amends loan agreement to access up to $150M tied to clinical and FDA milestones
First Amendment to Loan and Security Agreement with Hercules Capital dated December 18, 2025.
Arcus ends Phase 3 STAR-221 domvanalimab study on futility; no OS benefit
Phase 3 STAR-221 of domvanalimab + zimberelimab + chemo vs nivolumab + chemo stopped for futility after IDMC review.
Arcus Biosciences closes public offering of 15.76M shares, net proceeds ~$269.7M
Sold 15,755,000 shares at $18.25 per share including full exercise of underwriters' option.
Net loss of $135M for Q3 2025 vs $92M in Q3 2024; revenue $26M vs $48M.
Arcus Bio's EDGE-Gastric Ph2 shows median OS 26.7 months; ORR 59%
Median OS 26.7 months (90% CI: 18.4, NE) for all patients (n=41); PD-L1 high subgroup NE.
ARC-20 pooled analysis (n=121) in ccRCC: 31% confirmed ORR [95% CI 23-40], median PFS 12.2 mo (9.4-20.6).
Cash, cash equivalents & marketable securities: $927M at June 30, 2025 (Dec 31, 2024: $992M).
Arcus reports 46% confirmed ORR for casdatifan + cabozantinib in ccRCC post-immunotherapy
Phase 1/1b ARC-20 interim analysis shows 46% cORR (11/24) per RECIST v1.1; median follow-up 5.3 months.
Arcus Q1 net loss widens to $112M; cash $1.0B; casdatifan Phase 3 to start Q2
Revenue fell to $28M from $145M YoY; full-year 2025 revenue guidance $75M-$90M.
Arcus Q4 2024 net loss $94M; casdatifan shows best-in-class potential in ccRCC
Revenue $36M for Q4 2024 ($31M Q4 2023); net loss widened to $94M from $81M.
Arcus Biosciences raises ~$141.6M in public offering of 13.6M shares at $11.00/share
Offered 13,636,364 shares at $11.00/share, yielding ~$141.6M net proceeds after expenses.
Arcus reports $992M cash; Gilead opts out of casdatifan; ARC-20 data shows ORR 25-33%
Preliminary cash, cash equivalents and marketable securities of $992M as of Dec 31, 2024.
Arcus Q3 net loss $92M; casdatifan shows 34% ORR, domvanalimab 36% risk reduction
Net loss $92M vs $71M YoY; revenue $48M (up from $32M) on $41M license and development services.
Arcus Biosciences secures up to $250M term loan facility from Hercules Capital; initial $50M funded
Initial $50M funded; additional $50M available at company's option through Jun 2025 and another $50M through Mar 2026; final $100M at lenders' option.
Arcus reports Q2 2024 net loss $93M, cash $1.0B; casdatifan data due Q4
Revenue $39M (up from $29M in Q2 2023); net loss $93M vs $75M year-over-year.
Median PFS of 12.9 months (95% CI 9.8–13.8) across 41 patients in the domvanalimab+zimberelimab+chemo arm.
ARC-9 interim analysis: EZFB combo improves PFS (HR 0.27) and OS (HR 0.37) vs regorafenib in 3L mCRC
Cohort B (n=112) met primary endpoint: PFS HR 0.27 (p<0.0001), median 6.2 vs 2.1 months.
Revenue $145M vs $25M YoY, including $135M license revenue from Gilead collaboration amendments.
On February 6, 2025, the Board appointed Dietmar Berger M.D., Ph.D., as a Class II director to fill the vacancy left by Dr. Parsey's resignation.
On February 6, 2025, in connection with his departure from Gilead Sciences, Inc. (“Gilead”), Merdad Parsey, M.D., Ph.D., resigned as a member of Arcus Biosciences, Inc.’s (“Arcus”) Board of Directors (the “Board”), effective upon the appointment of Gilead’s new director designee pursuant to the Amended and Restated Investor Rights Agreement dated January 29, 2024 by and between Arcus and Gilead.
Richard Markus, M.D., Ph.D. has been appointed as the Company’s Chief Medical Officer, effective January 31, 2025
Dimitry Nuyten, M.D., Ph.D. will depart from the Company on January 31, 2025
Max materiality 0.80 · Median 0.70 · Most common event other_material